Streetbeat News

Products Services

BROS

Dutch Bros Inc. expanded significantly in Q4 2023, opening 37 new shops, with 32 being company-operated. Throughout 2023, they opened 159 new shops, 146 of which were company-operated. The company anticipates opening an additional 150-165 shops in FY24.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:15 pm

OLMA

Olema Oncology has nominated OP-3136 as a development candidate, marking a significant step in its pipeline development. This nomination could signal the progression of Olema's research into clinical development stages, potentially impacting the company's future prospects and investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:14 pm

BNGO

Bionano Genomics, Inc. (BNGO) reported preliminary Q4 and FY23 financial results, with Q4 revenue estimated between $10.4M-$10.7M, surpassing the $10.54M estimate, and FY23 revenue between $35.8M-$36.1M, slightly above the $35.94M estimate. The company achieved a 27%-30% increase in Q4 revenue and a 29%-30% increase in FY23 revenue compared to the previous year. Bionano also reported a 36% increase in installed OGM systems and a 67% increase in nanochannel array flowcells sold in Q4. The company achieved all 2023 ELEVATE milestones, including the release of the Stratys system and VIA software, and is preparing for the commercial launch of the Ionic Purification System in 2024. Bionano raised $11.0M from ATM sales and is focused on financial discipline to improve margins and extend cash runway.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:13 pm

DNLI

Denali Therapeutics has outlined its 2024 goals, focusing on completing enrollment in late-stage programs for MPS II and ALS, and preparing for commercialization. The company plans to advance its clinical-stage portfolio of seven therapeutic candidates targeting neurodegeneration, lysosomal storage diseases, and inflammatory disease. Denali is also progressing IND-enabling studies for Alzheimer's and Parkinson's disease treatments and prioritizing its preclinical portfolio with an emphasis on Transport Vehicle-enabled biotherapeutics.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:13 pm

BLUE

bluebird bio provided an update on its financial status and commercial launch plans for its gene therapies. The company reported approximately $275M in cash and cash equivalents, including restricted cash of about $53M. It anticipates 85 to 105 patient starts in 2024 across its commercial portfolio, with the first patient start for LYFGENIA expected in Q1 2024. bluebird has established agreements covering approximately 200 million U.S. lives and expects its funds to support operations into Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:11 pm

SSNLF

At CES 2024, Samsung Electronics Co Ltd. (OTCPK: SSNLF) showcased a prototype of its Transparent MicroLED display, a result of six years of R&D. The technology promises an immersive visual experience but remains expensive. Samsung's reveal follows LG's launch of the LG Signature OLED T, a transparent OLED TV, marking increased competition in the transparent display market.

Portfolio Pulse from Rounak Jain

January 08, 2024 | 1:10 pm

AEVA

Aeva has announced the introduction of Aeva Atlas, the first 4D LiDAR sensor designed specifically for mass production in automotive applications. This new sensor technology is expected to enhance the capabilities of autonomous and assisted driving systems by providing high-resolution perception data.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:07 pm

BFLY

Butterfly Network has received FDA clearance for its Butterfly iQ3, a handheld ultrasound system. This third iteration boasts an ergonomic design, doubled data processing speed, enhanced image resolution, sensitivity, penetration, and faster 3D capabilities with new automated image capture modes, iQ Slice and iQ Fan.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:05 pm

ATRI

HARP

TOI

Three health care stocks, Harpoon Therapeutics, Inc. (HARP), The Oncology Institute, Inc. (TOI), and Atrion Corporation (ATRI), are showing signs of being overbought according to their RSI values, which could indicate a potential short-term price decline. HARP has an RSI of 84.16 and recently received an Outperform rating from Oppenheimer with a price target of $23. TOI, with an RSI of 70.43, expanded its pharmacy operations, while ATRI, with an RSI of 71.03, reported a year-over-year decrease in Q3 financial results due to order deferrals and component shortages.

Portfolio Pulse from Avi Kapoor

January 08, 2024 | 1:05 pm

GEHC

GE HealthCare is set to acquire MIM Software, a provider of AI-enabled image analysis and workflow tools for various care areas. The terms of the acquisition were not disclosed, but it is aimed at enhancing GE HealthCare's precision care strategy and digital solutions.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:02 pm